QNTM Quantum Biopharma Ltd. IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1771885 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA—
ROIC (approx.)-230.2%
Asset turnover—
Leverage & solvency
Liabilities / assets54.3%
Debt / equity0.00x
Current ratio1.07x
Interest coverage-96.81x
Cash quality & payout
Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY2022*2022-12-31 | FY2021*2021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $2.76M | $6.08M | $3.86M | $6.91M | $6.33M |
| SG&A expense | $9.05M | $9.41M | $9.03M | $14.45M | $15.93M |
| Operating income | -$15.30M | -$16.14M | -$23.79M | -$27.43M | -$33.74M |
| Interest expense | $158,063 | $33,017 | $299 | $63,411 | $69,404 |
| Net income | — | — | — | $0 | $0 |
| EBITDA | -$14.76M | -$15.65M | -$21.28M | -$22.89M | -$29.70M |
| EPS (diluted) | — | — | — | — | — |
| Weighted avg. shares (diluted) | — | 1.14M | 609,056 | 595,883 | 34.95M |
| Banking | |||||
| Net interest income | $236,084 | $572,891 | $786,363 | $367,735 | $1,292 |
| Balance sheet | |||||
| Cash & equivalents | $1.91M | $6.00M | $2.76M | $16.98M | $35.26M |
| Short-term investments | $459,080 | $1.20M | $756,100 | $0 | $158,036 |
| Receivables | — | — | $209,550 | $374,377 | $500,964 |
| Inventory | $52,133 | $117,242 | $0 | — | — |
| Current assets | $6.48M | $12.05M | $11.09M | $17.85M | $45.93M |
| PP&E, netmay include right-of-use assets (IFRS) | $67,029 | $76,894 | $87,583 | $105,729 | $0 |
| Intangibles | $4.51M | $4.93M | $5.36M | $12.04M | $16.20M |
| Total assets | $11.16M | $17.12M | $17.47M | $38.41M | $62.96M |
| Current liabilities | $6.06M | $6.68M | $4.57M | $7.83M | $8.70M |
| Total liabilities | $6.06M | $6.68M | $4.57M | $7.87M | $8.83M |
| Shareholders' equity | $6.92M | $11.48M | $13.24M | $30.54M | $54.13M |
| Cash flow statement | |||||
| Operating cash flow | -$8.24M | -$6.88M | -$10.83M | -$28.33M | -$20.75M |
| Capital expenditure | — | $0 | $0 | $113,958 | $0 |
| Free cash flow | — | -$6.88M | -$10.83M | -$28.45M | -$20.75M |
| Investing cash flow | -$1.95M | -$1.50M | -$269,579 | $12.12M | $268,964 |
| Financing cash flow | $6.10M | $11.62M | -$3.13M | -$2.07M | $38.21M |
| Depreciation & amortization | $545,780 | $490,571 | $2.51M | $4.54M | $4.05M |
| Stock-based compensation | $2.95M | $152,214 | $3.84M | $1.53M | $7.44M |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company does not report gross profit in XBRL.
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.